Three teams of USC stem cell researchers have won a coveted prize — the opportunity to test 3,000 drug candidates or chemicals for the potential to help patients. Two teams will focus their efforts on cancer; the third will search for ways to accelerate the healing of large bone fractures.
The free screens will take place at the Choi Family Therapeutic Screening Facility, part of the Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research at USC. Andrew McMahon, director of the stem cell research center, is sponsoring the bone repair project, and Stephen Gruber, director of
Image via Wikipedia
Is there a future for stem cell therapies that don’t use embryonic stem cells? An international study involving EPFL has raised doubts, by showing that “reprogramming” adult stem cells leads to genetic aberrations.
It’s a discordant note in the symphony of good news that usually accompanies stem cell research announcements. Stem cells hold enormous promise in regenerative medicine, thanks to their ability to regenerate diseased or damaged tissues. They have made it possible to markedly improve the effectiveness of many medical treatments – muscle regeneration in cases of dystrophy, skin grafts for treating burn victims, and the
One in 10 adults in the U.S. — more than 20 million people — are suffering from some degree of chronic kidney disease. Kidney transplants offer a hope for cure, but thousands of patients die each year due to a shortage of donor organs. Even patients who are lucky enough to receive transplants run the risk of their immune systems rejecting the donor kidneys, and they have to take immunosuppressive drugs with serious side effects for the rest of their lives.
Vito Campese, professor and chair of the Keck School of Medicine of USC’s nephrology division, underscores the need to
The very first human trials of a treatment using induced pluripotent stem cells (iPS cells) in Japan will begin as early as next year, the government-backed Riken research institute announced on June 12.
Speaking at a meeting of the Japanese Society for Regenerative Medicine in Yokohama, research team leader Masayo Takahashi of the Riken Center for Developmental Biology detailed plans to begin using iPS treatments on patients with a degenerative eye condition. Transplanted iPS cells have not developed into cancer in animal testing, and the clinical trial will go ahead now that it’s confirmed that similar procedures do not pose
Official opening of Scottish Centre for Regenerative Medicine and bio-incubator facility, Nine, marks milestone in the growth of Edinburgh BioQuarter.
Research into conditions such as multiple sclerosis and heart and liver disease will benefit from multi-million stem cell research and life sciences facilities due to be opened today (Monday, 28th May) by HRH, the Princess Royal.
The Princess Royal unveiled plaques this afternoon at the £54 million Scottish Centre for Regenerative Medicine (SCRM) and £24 million bio-incubator facility, Nine, in Edinburgh.
The University of Edinburgh’s Scottish Centre for Regenerative Medicine will carry out cutting-edge stem cell research to help find therapies for